Healthcare stock to watch: Amedisys Inc (NASDAQ: AMED)

Free $100 Forex No-Deposit Bonus

Amedisys Inc (NASDAQ: AMED) posted mixed results for the fourth quarter of FY 19. The company’s Adjusted EBITDA were of $52.2 million as compared to $43.9 million in 2018. Adjusted net service revenue was of $500.7 million compared to $434.4 million in 2018. The company has reported increase in Adjusted EBITDA of $52.2 million compared to $43.9 million in 2018. Adjusted net service revenue had increased $500.7 million compared to $434.4 million in 2018. The company has delivered the adjusted net income attributable to Amedisys, Inc. of $31.1 million compared to $29.8 million in 2018. The adjusted net income attributable to Amedisys, Inc. of $31.1 million compared to $29.8 million in 2018. Further for FY 19, the company has delivered the Adjusted EBITDA of $225.3 million compared to $180.6 million in 2018. 2019 Adjusted net service revenue had increased to $1,961.6 million compared to $1,664.3 million in 2018. For FY 19, the company has reported the adjusted net income attributable to Amedisys, Inc. of $145.2 million compared to $122.1 million in 2018.

AMED in the fourth quarter of FY 19 has reported the adjusted earnings per share of 94 cents, beating the analysts’ estimates for the adjusted earnings per share of 93 cents, according to Zacks Investment Research. The company had reported the adjusted revenue of $500.7 million in the fourth quarter of FY 19, missing the analysts’ estimates for revenue of $510.4 million.

For the fiscal 2020, the company expects Net service revenue to be in the range of $2.115 billion to $2.160 billion. Adjusted EBITDA is projected to be in the range of $250 million to $260 million. 2020 Adjusted diluted earnings per share is expected to be in the range of $4.90 to $5.13 based on an estimated 33.4 million shares outstanding.

Moreover, in Clinical Distinction, the company has maintained at least 91% of all Home Health care centers achieving 4.0+. The company has expanded care centers on Medalogix Touch and Care products from approximately 10% to nearly 50% of the Home Health care center portfolio. In addition Home Health total admissions grew more than 7%. Hospice total ADC grew to approximately 11,200 from approximately 7,600 (~5%) via organic & inorganic growth. The company has acquired Compassionate Care Hospice (2/1), RoseRock Hospice (4/1) and signed Asana Hospice (closed 1/1/20). The company has signed innovative, nationwide Personal Care partnership agreement

Copyright © 2020. All Rights Reserved. FXDailyReport.Com
Risk Warning: Trading CFDs is a high risk activity and you may lose more than your initial deposit. You should never invest money that you cannot afford to lose. FXDailyReport.com will not accept any liability for loss or damage as a result of reliance on the information contained within this website including data, quotes, charts and buy/sell signals. Please be fully informed regarding the risks and costs associated with trading the financial markets.